drugset / Trial / NCT01079793

Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery

NCT01079793

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Ixabepilone may also make tumor cells more sensitive to radiation therapy. Giving radiation therapy with chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase I/II trial is studying the side effects and best dose of ixabepilone when given together with radiation therapy to see how well it works in treating patients with high-risk stage III prostate cancer after surgery.

Timeline

Start
2010-05-26
Primary completion
2011-10-17
Completion
2011-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixabepilone Small molecule Intravenous

Indications